March 15, 2012 – Chalfont, Pennsylvania – Genomind, a company specializing in neuropsychiatric personalized medicine, has promoted Chief Operating Officer Scott A. Storrer to president and CEO and announced two key additions to its leadership team. Collectively, these moves will facilitate the company’s continued growth and bolster its position as a leader in the development of genetic testing to help determine the best medication therapy approaches for patients with difficult to treat psychiatric conditions. The new team members include Senior Vice President of Clinical Operations and Strategy Jesen Fagerness, JD, and Director of Marketing Doreen M. Korba.
“The caliber of the individuals on our leadership team is indicative of the tremendous potential Genomind has in the development of genetic testing and personalized medicine,” said Ronald I. Dozoretz, MD, co-founder and chairman of Genomind. “It’s a very exciting time in the evolution of our company as we continue to build our commercial capacity, amass data through various studies and align resources to ensure that we’re offering the psychiatric community the absolute best in cutting-edge science to help patients get well.”
Mr. Storrer will oversee all aspects of Genomind’s operations, including strategy and growth financing. A 20-year healthcare industry veteran, he previously served as president and CEO of MEDecision, Inc., a leading health information technology company. Prior to that, Mr. Storrer was group president of Cardinal Health’s $81 billion pharmaceutical segment and executive vice president, service and information technology for the CIGNA Corporation. He has also held executive management positions with Liberty Mutual Group and GE’s financial management program.
Mr. Storrer holds a BA in Economics and Mathematics from DePauw University, an MBA from Boston University and has completed executive training at Harvard University.
Mr. Fagerness is responsible for ensuring that Genomind’s technology is cutting-edge and that its science is concrete and reproducible. He brings to his role more than a decade of experience with large-scale genetic research projects at leading institutions worldwide. He was most recently director of genomic research at the Psychiatric and Neurodevelopmental Genetics Unit of Massachusetts General Hospital and a visiting scientist at The Broad Institute. His past experience also includes roles with Bayer Pharmaceuticals and Genomics Collaborative. He has authored over 30 peer-reviewed publications in many high-impact journals.
Mr. Fagerness holds a BS in Chemistry from Eastern Washington University and a JD from Suffolk University Law School, where he focused his studies on intellectual property.
Ms. Korba is responsible for Genomind’s marketing strategy and execution, including brand development, brand awareness and internal and external communications. She has gained eight years of healthcare marketing experience, most recently as corporate marketing manager for MEDecision where she was instrumental in increasing brand awareness, successfully launching a major new product line and supporting the company’s growing sales efforts. She previously worked in marketing at Canyon Ranch Health Resort in Tucson, AZ where she was responsible for evaluating and instituting new educational programs.
Ms. Korba earned a BS in Interdisciplinary Health Services from Saint Joseph’s University and an MA in Counseling Psychology from Rosemont College.
About Genomind
Genomind is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information for clinicians to better understand the patient. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. Jay Lombard, DO, a neurologist, is Co-founder of Genomind and is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at genomind.com
